Clinical trial
Oral Estramustine and Oral Vinorelbine in the Treatment of Hormone-Refractory…
NCT00151086 · University of Michigan Rogel Cancer Center, Other · Completed
Key facts
| NCT number | NCT00151086 |
|---|---|
| Title | Oral Estramustine and Oral Vinorelbine in the Treatment of Hormone-Refractory Prostate Cancer |
| Official title | Phase I/II Evaluation of Oral Estramustine and Oral Vinorelbine on an Intermittent Schedule in Patients With Hormone-Refractory Adenocarcinoma of the Prostate |
| Lead sponsor | University of Michigan Rogel Cancer Center, Other |
| Collaborators | GlaxoSmithKline Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | Estramustine, Vinorelbine |
| Enrollment | 33 |
| Start date | Dec 1, 2001 |
| Primary completion | Mar 1, 2004 |
| Completion | Aug 1, 2006 |
| First posted | Sep 8, 2005 |
| Last update posted | Jan 22, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: